| Literature DB >> 26903712 |
Nathalie Deckx1, Inez Wens2, Amber H Nuyts1, Niel Hens3, Benedicte Y De Winter4, Gudrun Koppen5, Herman Goossens6, Pierre Van Damme7, Zwi N Berneman1, Bert O Eijnde2, Nathalie Cools1.
Abstract
Previously, we reported that patients with multiple sclerosis (MS) demonstrate improved muscle strength, exercise tolerance, and lean tissue mass following a combined endurance and resistance exercise program. However, the effect of exercise on the underlying disease pathogenesis remains elusive. Since recent evidence supports a crucial role of dendritic cells (DC) in the pathogenesis of MS, we investigated the effect of a 12-week combined exercise program in MS patients on the number and function of DC. We demonstrate an increased number of plasmacytoid DC (pDC) following the exercise program. These pDC display an activated phenotype, as evidenced by increased numbers of circulating CD62L(+) and CD80(+) pDC. Interestingly, the number of CD80(+) pDC positively correlates with the presence of IL-10-producing regulatory type 1 cells (Tr1), an important cell type for maintaining peripheral tolerance to self-antigens. In addition, decreased production of the inflammatory mediators, TNF-α and MMP-9, upon Toll-like receptor (TLR) stimulation was found at the end of the exercise program. Overall, our findings suggest that the 12-week exercise program reduces the secretion of inflammatory mediators upon TLR stimulation and promotes the immunoregulatory function of circulating pDC, suggestive for a favorable impact of exercise on the underlying immunopathogenesis of MS.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26903712 PMCID: PMC4745915 DOI: 10.1155/2016/6789276
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Flow diagram of patient enrolment.
Clinical details of the study population.
| EX | SED |
| |
|---|---|---|---|
| Gender (M/F) | 13/16 | 6/10 | 0.634 |
| Age ± SEM | 47 ± 2 | 50 ± 3 | 0.516 |
| BMI ± SEM | 24 ± 1 | 24 ± 1 | 0.821 |
| EDSS ± SEM | 3 ± 0.2 | 3 ± 0.4 | 0.155 |
| Type MS (CP/RR) | 10/19 | 5/11 | 0.826 |
| Medication (untreated/1st-line treatment/2nd-line treatment) | 4/16/9 | 2/8/6 | 0.908 |
Results are shown as mean ± SEM. Patients were defined as untreated when a wash-out period of at least 3 months was respected before recruitment in the study. 1st-line treatment: IFN-β (Avonex, Betaferon, and Rebif) and glatiramer acetate (Copaxone); 2nd-line treatment: alemtuzumab (Campath), natalizumab (Tysabri), and fingolimod (Gilenya).
EX, exercise group; SED, sedentary control group; M, male; F, female; BMI, body mass index; EDSS, expanded disability status scale; MS, multiple sclerosis; CP, chronically progressive MS; RR, relapsing-remitting MS; SEM, standard error of the mean.
Serum signaling molecule concentrations are not altered following long-term physical exercise in MS.
| Molecule | Group | Time | Mean concentration (pg/mL) ± SEM |
|
|---|---|---|---|---|
| IL-6 | EX | PRE | 0.60 ± 0.09 | 0.434 |
| POST | 0.54 ± 0.09 | |||
| SED | PRE | 0.45 ± 0.09 | 0.341 | |
| POST | 0.54 ± 0.09 | |||
|
| ||||
| IL-10 | EX | PRE | 0.48 ± 0.09 | 0.731 |
| POST | 0.50 ± 0.09 | |||
| SED | PRE | 0.60 ± 0.19 | 0.097 | |
| POST | 0.31 ± 0.04 | |||
|
| ||||
| IL-12p70 | EX | PRE | 0.09 ± 0.01 | 0.312 |
| POST | 0.12 ± 0.02 | |||
| SED | PRE | 0.13 ± 0.03 | 1.000 | |
| POST | 0.13 ± 0.02 | |||
|
| ||||
| TNF- | EX | PRE | 1.07 ± 0.11 | 1.000 |
| POST | 1.05 ± 0.10 | |||
| SED | PRE | 1.37 ± 0.18 | 0.665 | |
| POST | 1.23 ± 0.16 | |||
|
| ||||
| Caspase-1 | EX | PRE | 100.48 ± 9.78 | 0.217 |
| POST | 112.97 ± 9.81 | |||
| SED | PRE | 121.61 ± 25.43 | 1.000 | |
| POST | 100.00 ± 14.64 | |||
|
| ||||
| Molecule | Group | Time | Mean concentration (ng/mL) ± SEM |
|
|
| ||||
| MMP-9 | EX | PRE | 192.35 ± 23.43 | 1.000 |
| POST | 174.40 ± 17.84 | |||
| SED | PRE | 208.36 ± 25.59 | 0.368 | |
| POST | 176.32 ± 20.86 | |||
|
| ||||
| DHEA | EX | PRE | 16.11 ± 1.65 | 0.300 |
| POST | 17.06 ± 1.98 | |||
| SED | PRE | 16.08 ± 2.17 | 1.000 | |
| POST | 16.18 ± 1.90 | |||
|
| ||||
| Molecule | Group | Time | Mean concentration ( |
|
|
| ||||
| Cortisol | EX | PRE | 22.17 ± 1.73 |
|
| POST | 23.73 ± 1.74 | |||
| SED | PRE | 20.07 ± 1.00 | 0.110 | |
| POST | 21.49 ± 0.78 | |||
|
| ||||
| Molecule | Group | Time | Mean molar ratio ± SEM |
|
|
| ||||
| Cortisol/DHEA | EX | PRE | 13.78 ± 1.41 | 0.716 |
| POST | 14.50 ± 1.57 | |||
| SED | PRE | 12.18 ± 1.44 | 0.234 | |
| POST | 12.80 ± 1.34 | |||
The serum concentration of signaling molecules was measured with ELISA, and the molar ratio of cortisol to DHEA was calculated. Results are shown as mean concentration or molar ratio ± SEM.
IL, interleukin; TNF, tumour necrosis factor; MMP, matrix metalloproteinase; DHEA, dehydroepiandrosterone; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.
Figure 2Increased numbers of activated pDC are found following a 12-week combined exercise program in MS. Enumeration of the absolute number of circulating pDC (a) and cDC (b) was determined by means of a double platform method using an automatic cell counter and flow cytometry before start of the study (open bars) and after 12 weeks (filled bars). The activation state (c, d) and the migratory profile (e, f) of DC were assessed by enumerating pDC and cDC expressing CD80, CD86, CD62L, CCR5, and CCR7. Results are shown as mean absolute number ± SEM. P < 0.05. cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells; EX, exercise group; SED, sedentary control group; SEM, standard error of the mean.
A 12-week exercise program induces a decreased fold change of CCR5+ cDC upon LPS and IFN-γ stimulation and an increased fold change of HLA-DR+ pDC upon IQ stimulation.
| Marker | Group | Time | cDC | pDC | ||
|---|---|---|---|---|---|---|
| Mean fold change ± SEM |
| Mean fold change ± SEM |
| |||
| CCR5 | EX | PRE | 0.59 ± 0.06 |
| 1.45 ± 0.28 | 1.000 |
| POST | 0.38 ± 0.06 | 1.98 ± 0.61 | ||||
| SED | PRE | 0.51 ± 0.06 | 1.000 | 1.67 ± 0.37 | 0.184 | |
| POST | 0.56 ± 0.09 | 2.08 ± 0.98 | ||||
|
| ||||||
| CD86 | EX | PRE | 2.68 ± 0.45 | 0.100 | 12.34 ± 2.55 | 0.383 |
| POST | 2.12 ± 0.23 | 9.14 ± 2.11 | ||||
| SED | PRE | 2.44 ± 0.48 | 1.000 | 5.70 ± 1.56 | 0.767 | |
| POST | 2.84 ± 0.69 | 5.95 ± 2.73 | ||||
|
| ||||||
| HLA-DR | EX | PRE | 1.01 ± 0.01 | 0.189 | 0.90 ± 0.03 |
|
| POST | 1.01 ± 0.01 | 0.97 ± 0.02 | ||||
| SED | PRE | 1.06 ± 0.06 | 0.439 | 0.92 ± 0.06 | 0.609 | |
| POST | 1.06 ± 0.03 | 0.82 ± 0.08 | ||||
Blood samples were stimulated overnight with LPS in combination with IFN-γ, or IQ. The percentage of CCR5, CD86, and HLA-DR positive cDC and pDC after TLR stimulation was measured using flow cytometry. Mean fold changes are calculated as the ratio of the proportion of CCR5, CD86, and HLA-DR positive cDC and pDC in the stimulated condition to the nonstimulated condition. Results are shown as mean fold change ± SEM.
cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells; LPS, lipopolysaccharide; IQ, imiquimod; EX, exercise group; SED, sedentary group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.
Exercise results in decreased secretion of the inflammatory mediators, TNF-α and MMP-9, upon LPS and IFN-γ stimulation.
| Inflammatory mediator | Group | Time | LPS + IFN- | IQ | ||
|---|---|---|---|---|---|---|
| Mean fold change ± SEM |
| Mean fold change ± SEM |
| |||
| IL-1 | EX | PRE | 89.3 ± 11.5 | 0.461 | 2.2 ± 0.2 | 0.790 |
| POST | 77.1 ± 11.5 | 2.0 ± 0.2 | ||||
| SED | PRE | 94.1 ± 19.5 | 0.258 | 2.7 ± 0.6 |
| |
| POST | 72.0 ± 16.9 | 1.8 ± 0.4 | ||||
|
| ||||||
| IL-6 | EX | PRE | 111.0 ± 7.7 | 1.000 | 15.7 ± 2.1 | 1.000 |
| POST | 110.8 ± 6.5 | 15.9 ± 2.5 | ||||
| SED | PRE | 103.5 ± 12.8 | 0.782 | 16.8 ± 3.1 | 1.000 | |
| POST | 109.7 ± 11.0 | 14.5 ± 3.4 | ||||
|
| ||||||
| IL-12p70 | EX | PRE | 26.0 ± 7.6 | 0.313 | 1.2 ± 0.1 | 1.000 |
| POST | 15.2 ± 4.1 | 1.2 ± 0.2 | ||||
| SED | PRE | 18.1 ± 6.4 | 1.000 | 1.6 ± 0.4 | 0.410 | |
| POST | 19.5 ± 6.8 | 2.2 ± 0.6 | ||||
|
| ||||||
| TNF- | EX | PRE | 55.1 ± 5.7 |
| 1.6 ± 0.1 | 0.926 |
| POST | 39.2 ± 4.4 | 1.5 ± 0.1 | ||||
| SED | PRE | 43.9 ± 8.0 | 1.000 | 1.6 ± 0.2 | 0.168 | |
| POST | 46.5 ± 9.3 | 1.3 ± 0.2 | ||||
|
| ||||||
| IFN- | EX | PRE | 2.1 ± 0.6 | 1.000 | 7.4 ± 1.2 | 1.000 |
| POST | 2.7 ± 0.9 | 8.0 ± 1.6 | ||||
| SED | PRE | 1.9 ± 0.8 | 1.000 | 6.7 ± 1.8 | 0.231 | |
| POST | 1.7 ± 0.6 | 4.4 ± 1.0 | ||||
|
| ||||||
| Caspase-1 | EX | PRE | 8.8 ± 0.7 | 0.604 | 4.8 ± 0.7 | 0.260 |
| POST | 8.0 ± 0.7 | 3.6 ± 0.4 | ||||
| SED | PRE | 8.1 ± 1.0 | 1.000 | 3.6 ± 0.6 | 1.000 | |
| POST | 6.8 ± 0.8 | 3.8 ± 0.9 | ||||
|
| ||||||
| MMP-9 | EX | PRE | 7.9 ± 0.8 |
| 2.2 ± 0.2 | 1.000 |
| POST | 6.2 ± 0.5 | 2.1 ± 0.1 | ||||
| SED | PRE | 6.5 ± 1.0 | 0.233 | 2.0 ± 0.2 | 1.000 | |
| POST | 6.4 ± 0.6 | 2.0 ± 0.3 | ||||
Blood samples were stimulated overnight with LPS in combination with IFN-γ, or IQ. Secretion of inflammatory mediators was quantified using ELISA. Mean fold changes are calculated as the ratio of the secreted concentration in the stimulated condition to the nonstimulated condition. Results are shown as mean fold change ± SEM.
LPS, lipopolysaccharide; IQ, imiquimod; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; MMP, matrix metalloproteinase; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.
Circulating Treg subsets are not affected by long-term physical exercise in MS.
| Treg subset | Group | Time | Mean % Treg in CD4+ T cell population ± SEM |
|
|---|---|---|---|---|
| CD25hiFoxP3+ | EX | PRE | 0.62 ± 0.11 | 0.083 |
| POST | 1.12 ± 0.41 | |||
| SED | PRE | 1.00 ± 0.30 | 0.782 | |
| POST | 1.69 ± 0.85 | |||
|
| ||||
| IL-10+ (Tr1) | EX | PRE | 0.22 ± 0.05 | 1.000 |
| POST | 0.20 ± 0.02 | |||
| SED | PRE | 0.33 ± 0.09 | 0.796 | |
| POST | 0.50 ± 0.26 | |||
|
| ||||
| TGF- | EX | PRE | 0.15 ± 0.02 | 1.000 |
| POST | 0.19 ± 0.09 | |||
| SED | PRE | 0.17 ± 0.04 | 0.056 | |
| POST | 0.12 ± 0.08 | |||
The percentage of circulating Treg subsets was determined using flow cytometry. Results are shown as mean percentage ± SEM.
Treg, regulatory T cell; FoxP3, forkhead box P3; IL, interleukin; Tr1, type 1 regulatory T cell; TGF, transforming growth factor; Th3, T helper 3 cell; EX, exercise group; SED, sedentary control group; PRE, baseline measurement; POST, measurement after 12 weeks; SEM, standard error of the mean.
Figure 3Positive correlation at log-log scale between the proportion of Tr1 and the number of CD80+ pDC. A positive correlation at log-log scale was found between the proportion of Tr1 cells and the number of CD80+ pDC (P = 0.001; ρ = 0.383). Both variables were log-transformed to obtain a normal distribution. pDC, plasmacytoid dendritic cells; Tr1, type 1 regulatory T cell; log, logarithmic transformation; ρ, Pearson's correlation coefficient.